Since over 70 percent of prostate cancer cases are diagnosed at age 65 years or older, aging is suspected to be involved in the development of the disease. However, little is known about the mechanism underlying the link between aging and prostate cancer risk. Aging is a biological process governed by a series of molecular and biochemical changes, many of which are manifested by abnormal increases or decreases in gene expression. Suppression of gene transcription through DNA methylation is an important mechanism in regulation of gene expression, and DNA methylation in certain genes increases with age. DNA methylation has also been found frequently in cancer, and many genes with important functions against malignant transformation, such as tumor suppressor genes, detoxification genes, and DNA repair genes, are silenced in cancer due to methylation. The parallel of methylation-suppressed gene expression in the elderly and in cancer patients suggests that DNA methylation may explain in part the increased risk of prostate cancer seen in older men. Despite this observation, no epidemiologic evidence exists concerning the hypothesis that age-related systemic increases in DNA methylation in tumor suppressor genes, detoxification genes, and DNA repair genes occur, and that these increases relate to prostate cancer risk. In this proposal, we will examine this hypothesis by determining if: a) CpG island promoter methylation is increased with age in a tumor suppressor gene, a detoxification gene, and a DNA repair gene; b) CpG island methylation in these genes is higher in African-Americans than in Caucasians; c) CpG island methylation in these genes is higher in prostate cancer patients than in age- and race-matched healthy controls; and d) CpG methylation in these genes is associated with other age-related biomarkers. To achieve these goals, we will analyze blood samples collected from 1,697 men who participated in a prostate cancer screening program during 1998-2000. Plasma and peripheral blood cell DNA will be analyzed for DNA methylation using methylation-specific PCR. Plasma biomarkers will be analyzed using ELISA. The findings of this study will provide insights into the possible mechanism between aging and prostate cancer and may lead to development of new markers.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project (R01)
Project #
5R01AG021392-03
Application #
6753511
Study Section
Special Emphasis Panel (ZAG1-FAS-9 (M3))
Program Officer
Yancik, Rosemary
Project Start
2002-07-01
Project End
2006-06-30
Budget Start
2004-07-01
Budget End
2006-06-30
Support Year
3
Fiscal Year
2004
Total Cost
$245,250
Indirect Cost
Name
Yale University
Department
Public Health & Prev Medicine
Type
Schools of Medicine
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Qian, Biyun; Katsaros, Dionyssios; Lu, Lingeng et al. (2011) IGF-II promoter specific methylation and expression in epithelial ovarian cancer and their associations with disease characteristics. Oncol Rep 25:203-13
Brokaw, Jane; Katsaros, Dionyssios; Wiley, Andrew et al. (2007) IGF-I in epithelial ovarian cancer and its role in disease progression. Growth Factors 25:346-54
Beeghly, A C; Katsaros, D; Wiley, A L et al. (2007) IGF-II promoter methylation and ovarian cancer prognosis. J Cancer Res Clin Oncol 133:713-23
Lu, Lingeng; Katsaros, Dionyssios; Wiley, Andrew et al. (2006) Promoter-specific transcription of insulin-like growth factor-II in epithelial ovarian cancer. Gynecol Oncol 103:990-5
Lu, Lingeng; Katsaros, Dionyssios; Wiley, Andrew et al. (2006) The relationship of insulin-like growth factor-II, insulin-like growth factor binding protein-3, and estrogen receptor-alpha expression to disease progression in epithelial ovarian cancer. Clin Cancer Res 12:1208-14
Wiley, Andrew; Katsaros, Dionyssios; Chen, Haigang et al. (2006) Aberrant promoter methylation of multiple genes in malignant ovarian tumors and in ovarian tumors with low malignant potential. Cancer 107:299-308